Genhouse Bio

Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026

Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with...

Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026

Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong...

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026

Genhouse Bio, a small‑molecule oncology company incubated by Viva Biotech, announced the completion of a...

Company Drug

Genhouse Bio’s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals

Fineline Cube Jan 6, 2026

Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China’s...

Company Drug

Hope Medicine Doses First Patient in HMI-115 Phase III – First-in-Class Non-Hormonal Endometriosis Therapy Advances in China

Company Drug

Kelun‑Biotech’s SKB103 Wins NMPA Approval – Novel TAA‑PD‑L1 Bispecific ADC Enters Clinical Trials for Advanced Solid Tumors

Company

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer